Donate

AbbVie's New Crohn's Disease Drug Candidate

Home»Health»Intestinal Disease»Crohns»AbbVie’s New Crohn’s Disease Drug Candidate

AbbVie’s drug is currently the best-selling medication on the planet, and it is approved to treat a wide range of diseases, including Crohn’s Disease and . Recently, the company announced a partnership with a small called to develop a JAK1 inhibitor for Crohn’s Disease. In the following video, health-care analyst Max Macaluso discusses the details behind this deal and how this drug can potentially help the company maintain its lead in the market in the coming years.

AbbVie's New Crohn's Disease Drug Candidate – The Motley Fool
Motley Fool
AbbVie's (NYSE: ) drug Humira is currently the best-selling medication on the planet, and it is approved to treat a wide range of diseases, including Crohn's Disease and ulcerative colitis. Recently, the company announced a partnership with a
AbbVie and Galapagos Extend GLPG0634 Collaboration

all 2 news articles »

You must be logged in to post a comment Login

No Guts Know Glory

IDEAS Kids

IDEAS Kids

IBD Adventures